Top 10 states for pharmacists in 2019

Amy Baxter | | Health Exec | Management

Minnesota is the best place to be a pharmacist in 2019, according to a new ranking from Drug Topics. The state has come first in numerous lists over the past several years, including best state for healthcare in 2019 by WalletHub.

Drug Topics pulled together data from the Bureau of Labor Statistics, WalletHub and U.S. News and World Report to come up with its list, measuring nine factors overall, such as average annual salary, cost of living, employment, stress levels and more.

Here are the top 10 best states for pharmacists in 2019:

1. Minnesota

2. Kentucky

3. Michigan

4. Pennsylvania

5. Iowa (tie)

5. Ohio (tie)

7. Arizona

8. Illinois (tie)

8. Wisconsin (tie)

10. Nebraska

Despite being ranked No. 1 overall, Minnesota was given the worst score (50 on a scale of 1-50) for stress levels.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.